{"id":"W4404567325","doi":"10.1136/jitc-2024-010143","title":"Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)","year":2024,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Alberta Health Services; Université Laval; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; CD8; Cytokine; Oncology; Response Evaluation Criteria in Solid Tumors; Melanoma; Aldesleukin; Adverse effect; Cancer; Interleukin 2; Gastroenterology; Immunotherapy; Immunology; Phases of clinical research; Toxicity; Cancer research; Immune system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00109866,0.000437875,0.0009819097,0.0002778685,0.000232341,0.0004721278,0.0002666238,0.0003999096,0.0007475744],"category_scores_gemma":[0.0005244384,0.0001914309,0.0004606803,0.0002985061,0.0004903848,0.0004641626,0.000275916,0.0007668615,0.0001951413],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004547275,"about_ca_system_score_gemma":0.0007179716,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003751282,"about_ca_topic_score_gemma":0.0007842746,"domain_scores_codex":[0.9995579,0.0002159139,0.00003459063,0.0000849639,0.00004525478,0.00006140397],"domain_scores_gemma":[0.9996685,0.00008122984,0.00006508936,0.00002651251,0.00002131256,0.0001374309],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5288655,0.03750942,0.07041649,0.001156162,0.000894688,0.0006599451,0.0005797153,0.00633873,0.1465655,0.0003163744,0.001605506,0.205092],"study_design_scores_gemma":[0.09138531,0.7924673,0.08894119,0.00006238027,0.0005698251,0.0008728399,0.0001878137,0.001765468,0.01912947,0.0001619128,0.004420739,0.00003578571],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976464,0.001272561,0.00011341,0.00004872416,0.00001536661,0.0002444284,0.0001088086,0.00001140317,0.0005388078],"genre_scores_gemma":[0.9986002,0.0004058522,0.000347996,0.00006589732,0.00002981518,0.000169525,0.0001539475,0.000001856378,0.0002248228],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00109866,"threshold_uncertainty_score":0.00581038,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007401104382701864,"score_gpt":0.3007189979122338,"score_spread":0.293317893529532,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}